Wei Qi    Associate Professor
InstituteSchool of Life Science and Technology
Research AreaEpigenetics and Translational Research
Contact Info.qiwei@@shanghaitech.edu.cn

1995-1999 BS, School of Life Sciences, Nanjing University, China
1999-2001 MS, School of Life Sciences, Nanjing University, China
2002-2006 PhD, Southwestern Medical Center at Dallas, University of Texas, USA
2007-2008 Research Associate Professor, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences
2008-2018 Investigator and Senior Investigator, Novartis Institutes for BioMedical Researches, Shanghai
2018.3- Associate Professor, Principle Investigator, School of Life Science and Technology, ShanghaiTech University

Research Interests
Histone modification is a major epigenetic factor modifying gene transcription on top of inherited genetic information. It regulates cellular status such as proliferation and differentiation and designates the identity of specific cells. The machinery for histone modification is composed of writers (enzymes adding the modification to histones), erasers (enzymes removing the modification) and readers (proteins recognizing the modification and transduce signals). Mutation or dysfunction of these epigenetic machineries has been implicated in multiple diseases such as cancer, autoimmune diseases and metabolic diseases. 
My lab is focusing on dissecting the epigenetic characteristics of the disease and validating their pathophysiological functions using integrated approaches of epigenetics, chemical biology and gene editing. The goal of our work is to identify effective targets and potential lead compounds for therapeutic development, so that the patients will benefit.

Selected Publications

1.    Qi W#, Zhao K#, Gu J#, Huang Y#, Wang Y, Zhang H, Zhang M, Zhang J, Yu Z, Li L, Teng L, Chuai S, Zhang C, Zhao M, Chan H, Chen Z, Fang D, Fei Q, Feng L, Feng L, Gao Y, Ge H, Ge X, Li G, Lingel A, Lin Y, Liu Y, Luo F, Shi M, Wang L, Wang Z, Yu Y, Zeng J, Zeng C, Zhang L, Zhang Q, Zhou S, Oyang C, Atadja P and Li E. (2017). An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.Nat Chem Biol. doi: 10.1038/nchembio.2304 (#: These authors contributed equally.)

2.  Chen Y, Kim J, Zhang R, Yang X, Zhang Y, Fang J, Chen Z, Teng L, Chen X, Ge H, Atadja P, Li E, Chen T and Qi W*.(2016). Histone Demethylase LSD1 Promotes Adipocyte Differentiation through Repressing Wnt Signaling.Cell Chem Biol.23(10):1228-1240

3.   Gibaja V, Shen F, Harari J, Korn J, Ruddy D, Saenz-Vash V, Zhai H, Rejtar T, Paris PC, Yu Z, Lira M, King D, Qi W, Keen N, Hassan AQ, Chan H. (2015). Development of secondary mutations in wild type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene. 35(5):558-566

4.    Qi W#, Chan H#, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan X, Fang J, Mi Y, Zhang M, Zhou T, Feng G, Chen Z, Li G, Yang T, Zhao K, Liu X, Yu Z, Lu CX, Atadja P and Li E. (2012). Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.Proc Natl Acad Sci U S A.109(52):21360-5 (#: These authors contributed equally.)